Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date

Metformin is the first-line therapy for the management of type 2 diabetes. After 3 months of metformin, add-on therapy can be considered if an individual’s glycemic control has not been achieved for hemoglobin A1c, fasting blood glucose levels, and postprandial blood glucose levels. Liraglutide is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Howell, Rebecca, Wright, Adrienne M, Clements, Jennifer N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475096/
https://www.ncbi.nlm.nih.gov/pubmed/31118715
http://dx.doi.org/10.2147/DMSO.S174568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475096/
https://www.ncbi.nlm.nih.gov/pubmed/31118715
http://dx.doi.org/10.2147/DMSO.S174568

Ejemplares similares